http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9295682-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a4a890467771017dd3607dba93118808 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-243 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-661 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-243 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-661 |
| filingDate | 2009-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36b551762afd101a0e37d053b649c650 |
| publicationDate | 2016-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-9295682-B2 |
| titleOfInvention | Adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of clinical manifestations associated with diseases like cachexia and correction of adverse effects of drugs such as immunosuppression, neutropenia and lymphopenia, comprising the association or combination of a biological response modifier specially selected and other substances with antineoplastic action and/or other treatments |
| abstract | The present invention comprises a new combination or association of pharmacologically active substances and/or non-drug treatments for cancer. According to the present invention, the combination or association of substances and/or non-drug treatments is used to treat cancer, clinical problems associated to cancer and adverse side effects related to substances and/or treatments used to fight this illness. The components of the combination or association of substances, the biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) and at least one substance and/or treatment with antineoplastic properties can be jointly or simultaneously or consecutively or sequentially administered in an appropriate form, according to their chemical properties, and with the use of the most suitable procedures, and also in the most therapeutically effective dose and use. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11136242-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11623869-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11639294-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11572284-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10716815-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10314865-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9730967-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10350188-B2 |
| priorityDate | 2009-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 370.